Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Abroad (travel likely)RecruitingPHASE2

Conditions

Non Small Cell Lung Cancer · EGFR Gene Mutation · ALK Gene Mutation · ROS1 Gene Mutation · MET Gene Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Yongchang Zhang, Changsha, Hunan, China
Contact: Study coordinator (Yongchang Zhang, MD) · zhangyongchang@csu.edu.cn · +8613873123436

Study leads

Yongchang Zhang, MD
Principal Investigator
Hunan Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non Small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Huntersville, United States · Oklahoma City, United States

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IV · EGFR Gene Mutation

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Non Small Cell Lung Cancer NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Neimeng, China · Neimeng, China

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Non Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China